GlassScriptPhysician profile
Craig B Primack
NPI 1093707374
$75,039.18
in general payments reported to CMS, 2019-2025
6 companies · $20.94 in 2025
The $20.94 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $1,832 · 2021: $19K · 2022: $15K · 2023: $16K · 2024: $12K · 2025: $20.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Honoraria: $1,604 · Travel and Lodging: $1,383 · Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,406.25 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,250.00 |
| Honoraria | $1,604.00 |
| Travel and Lodging | $1,383.06 |
| Food and Beverage | $1,024.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $24,554.33 | 2021-2023 | Contrave |
| Novo Nordisk INC | $20,258.59 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Nestle Healthcare Nutrition INC. | $18,000.00 | 2022-2023 | |
| Lilly USA, LLC | $12,180.33 | 2023-2024 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $33.23 | 2019 | |
| Allergan, INC. | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Primack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.